

## Communiqué from Genovis AB (publ) Annual General Meeting May 15, 2024

The Annual General Meeting adopted the following resolutions:

- The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted.
- The Board and the Chief Executive Officer were discharged from liability.
- The Board shall consist until the next AGM of five ordinary members without deputies.
- Re-election of Board members Torben Jørgensen, Mikael Lönn, Lotta Ljungqvist, Steve Jordan and Magnus Gustafsson.  
Torben Jørgensen was elected Chairperson of the Board.
- Remuneration will be paid to the Board of Directors in the amount of SEK 220,000 to Board members and SEK 500,000 to the Chairperson of the Board.
- Remuneration to the auditors will be paid on approved account.
- In accordance with the Nomination Committee's proposal, the Meeting re-elected the accounting firm Öhrlings PricewaterhouseCoopers AB as auditor for the period until the close of the Annual General Meeting 2025.
- A Nomination Committee will be formed with representatives of the four largest shareholders on September 30, 2024.
- The AGM resolved on the authorization to issue shares with or without preferential rights for existing shareholders. As a result of this resolution, share capital could increase by a maximum of SEK 1,625,000 through the issuance of a maximum of 6,500,000 shares.

---

Minutes with all resolutions from the meeting will be made available on the company's website:  
<https://investor.genovis.com/en/corporate-governance/general-meeting/>

For more information, please contact: Fredrik Olsson, CEO, Genovis AB, T: +46 (0)70-276 46 56  
Email: [fredrik.olsson@genovis.com](mailto:fredrik.olsson@genovis.com)

**Genovis'** business concept is to apply its knowledge and customer driven innovation to design and provide tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Carnegie Investment Bank AB (publ) is the Company's Certified Adviser, email: [certifiedadviser@carnegie.se](mailto:certifiedadviser@carnegie.se).